Tobias Gerhard, PhD
Associate Professor
Ernest Mario School of Pharmacy and Institute for Health, Health Care Policy and Aging Research
Rutgers University
Tobias Gerhard (PhD, Pharmacoepidemiology, University of Florida, 2007; BS, Pharmacy, Albert-Ludwigs University, Germany, 2002) is an associate professor of Pharmacoepidemiology at the Rutgers Ernest Mario School of Pharmacy. He also serves as Associate Director of the Center for Health Services Research on Pharmacotherapy, Chronic Disease Management, and Outcomes at the Rutgers Institute for Health, where he conducts research on use, safety, and outcomes of prescription drugs, particularly those used to treat mental health conditions. He is interested in epidemiological methods and their applications in the analysis of large administrative databases and has published and presented on a wide range of topics including attention deficit hyperactivity disorder, autism spectrum disorders, cardiovascular disease, epidemiological methods, pharmacogenetics, and pharmacoeconomics.
His current research includes the comparative safety and effectiveness of antipsychotic medications, pharmacological treatments for dementia, and more generally research on the use and management of psychotropic medications in Medicaid, Medicare, and privately insured populations. He is a Fellow and Board Member of the International Society for Pharmacoepidemiology (ISPE) and currently serves on FDA’s Drug Safety and Risk Management Advisory Committee. Dr. Gerhard is the recipient of a NARSAD Young Investigator Award, a NCDEU New Investigator award and currently serves as Co-Principal Investigator of the AHRQ-funded Rutgers Center for Education and Research on Mental Health Therapeutics (CERTs).
Gagne JJ, Fireman B, Ryan PB, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012 Jan;21(Suppl 1):32-40. doi: 10.1002/pds.2316.
Gerhard T, Akincigil A, Correll CU, Foglio N, Crystal S, Olfson M. National Trends in Second Generation Antipsychotic Augmentation for Non-Psychotic Depression. J Clin Psychiatry. 2014 Jan 7. [Epub ahead of print]
Huybrechts K, Gerhard T, Myers JA, Levin R, Crystal S, Schneeweiss S. Instrumental variable analysis for comparative effectiveness studies in nursing home populations: Validity of instruments based on nursing home prescribing preferences. Pharmacoepidemiol Drug Saf. 2013 Mar 24. [Epub ahead of print]
Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, Devanand DP, Lucas JA, Huang C, Malka ES, Levin R, Crystal S. Comparative Mortality Risks of Antipsychotic Medications in Community Dwelling Older Adults. Br J Psychiatry. 2013 August 8. [Epub ahead of print]. PMID: 23929443
Johnson E, Bartman B, Briesacher B, Fleming N, Gerhard T, Kornegay C, Nourjah P, Sauer B, Schumock G, Sedrakyan A, Sturmer T, West S, Schneeweiss S. The Incident User Design in Comparative Effectiveness Research. Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):1-6. PMID: 23023988
Gerhard T, Delaney JAC, Shuster J, Brumback B, Johnson JA, Pepine C, Winterstein AG. Estimating Effects of Antihypertensive Therapy on Adverse Cardiovascular Outcomes in the Presence of Time-Dependent Confounding by Blood Pressure. BMC Medical Research Methodology 2012,12:119.
Winterstein AG, Gerhard T, Kubilis P, Linden S, Shuster J, Zito J, Crystal S, Olfson M. Cardiovascular safety of central nervous system stimulants in children and adolescents. BMJ 2012;345:e4627. PMID: 22809800
Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn, J, Levin R, Lucas J, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344:e977. PMCID: PMC3285717
Olfson M, Huang C, Gerhard T, Crystal S, Winterstein AG, Marcus S. Stimulants and Vascular Events in Youth with Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2012;(51)2:147-156. PMCID: PMC3266532
Olfson, M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S. Comparative Effectiveness of Second Generation Antipsychotic Medications in Early Onset Schizophrenia. Schizophr Bull. 2012;38(4):845-53. PMCID: PMC3406514
Crystal S, Gaboda D, Lucas J, Gerhard T, Chakravarty S. Assessing Medication Exposures and Outcomes in the Frail Elderly: Research Challenges in Nursing Home Pharmacotherapy. Medical Care. 2010;48(6):S23-S31. PMID: 20473191
Gerhard T, Winterstein AG, Olfson M, Huang C, Saidi A, Crystal, S. Pre-Existing Cardiovascular Conditions and Pharmacological Treatment of Adult ADHD. Pharmacoepidemiol Drug Saf. 2010;19(5):457-64. PMID: 20232490
Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened Use of Atypical Antipsychotic Drugs: Safety, Effectiveness, and Policy Challenges. Health Affairs. 2009;28(5): w770-w781. PMCID: PMC2896705
Gerhard T, Chavez B, Olfson M, Crystal S. National Patterns in the Outpatient Pharmacological Management of Children and Adolescents with Autism Spectrum Disorder. J Clin Psychopharm. 2009;29(3):307-310. PMID: 19440093
Winterstein AG, Gerhard T, Shuster JJ, Johnson M, Zito JM, Saidi A. Cardiac Safety of Methylphenidate versus Amphetamine Salts. Pediatrics. 2009:124(1):e75-80. PMID: 19564272
Gerhard T. Bias: Considerations for Research Practice. Am J Health Syst Pharm. 2008; 15;65(22):2159-68. PMID: 18997149
